Showing results (1601-1610 of 1,811) with videos related to

Sort By:
Pageof 182
Cancer|June 11, 2016
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapiesJeffrey S Ross, Laurie M Gay, Kai Wang, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 2, 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT TrialAndrea Gabrio, Necdet B Gunsoy, Gianluca Baio, et al.
ERJ Open Research|March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysisMeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
The Oncologist|April 19, 2019
Sicca Syndrome Associated with Immune Checkpoint Inhibitor TherapyBlake M Warner, Alan N Baer, Evan J Lipson, et al.
Journal of Medicinal Chemistry|January 15, 1999
Carboxy-substituted cinnamides: a novel series of potent, orally active LTB4 receptor antagonistsP D Greenspan, R A Fujimoto, P J Marshall, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 21, 2026
Use of supportive care services and advance care planning among early phase oncology clinical trial participantsLeah L Thompson, Megan Healy, Virginia Capasso, et al.
Nature Immunology|July 15, 2020
Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunityChang Liu, Ashwin Somasundaram, Sasikanth Manne, et al.
Head & Neck|March 19, 2015
Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinomaMatthew G Fury, Han Xiao, Eric J Sherman, et al.
Advances in Therapy|July 11, 2020
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
Journal of Translational Medicine|July 6, 2015
Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant settingEvan J Lipson, William H Sharfman, Shuming Chen, et al.
Pageof 182